Published in BMC Cancer on July 04, 2014
A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol (2014) 1.24
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer (2014) 0.90
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. BMC Cancer (2015) 0.86
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. Mol Cell Oncol (2015) 0.86
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. Oncotarget (2016) 0.80
UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget (2016) 0.75
Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry. Cell Cycle (2016) 0.75
Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase. Oncotarget (2016) 0.75
Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage. Sci Rep (2017) 0.75
NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. Oncotarget (2017) 0.75
Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells. Neoplasia (2017) 0.75
Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev (2000) 11.49
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res (2010) 4.44
Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell (2008) 3.15
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther (2008) 3.07
New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res (2010) 2.82
G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther (2004) 2.50
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer (2008) 2.33
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res (2010) 2.06
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther (2008) 2.04
Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol Cell Biol (2007) 1.87
Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle (2005) 1.59
Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci (2011) 1.55
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther (2011) 1.51
Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today (2011) 1.46
Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker. Aging (Albany NY) (2011) 1.36
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle (2010) 1.35
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin Cancer Res (2010) 1.35
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res (2011) 1.29
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today (2009) 1.24
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 1.20
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res (2012) 1.20
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther (2010) 1.13
Regulation of chk1. Cell Div (2009) 1.12
Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. J Biol Chem (2003) 1.09
Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. Mol Cancer Res (2012) 1.06
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol (2013) 1.05
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs (2013) 1.02
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs (2012) 1.01
Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC Cancer (2013) 0.99
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor. Mol Cancer Ther (2013) 0.97
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. Mol Cancer Ther (2013) 0.94
Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death. Cell Cycle (2013) 0.90
Death of p53-defective cells triggered by forced mitotic entry in the presence of DNA damage is not uniquely dependent on Caspase-2 or the PIDDosome. Cell Death Dis (2013) 0.88
Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor. PLoS One (2010) 0.87
Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors. Biomarkers (2008) 0.87